Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blomia tropicalis allergen extract skin prick test unit determination
2024-515169-33-00Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Oct 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blomia tropicalis allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma, sponsored by Inmunotek. Primary endpoint: Primary wheal area measurement. Started Oct 2025; status: completed.
02
Drugs
blomia tropicalis allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2024-515169-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515169-33-00.